Weiss Ratings Reiterates Sell (E+) Rating for Equillium (NASDAQ:EQ)

Key Points

• Weiss Ratings has reaffirmed a "sell (e+)" rating for Equillium (NASDAQ:EQ), indicating ongoing concerns about the stock's performance.
• Equillium's stock has dropped 1.3%, trading at $1.47, with a 12-month range between $0.27 and $2.35.
• The company's latest earnings report showed a loss of ($0.16) EPS, missing analyst expectations of ($0.14) by $0.02.

Equillium (NASDAQ:EQ - Get Free Report)'s stock had its "sell (e+)" rating reissued by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Equillium to a "sell" rating in a research note on Friday, September 5th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Equillium currently has a consensus rating of "Reduce" and an average target price of $1.00.

Equillium Stock Down 1.3%

EQ opened at $1.47 on Wednesday. Equillium has a 12-month low of $0.27 and a 12-month high of $2.35. The stock has a market cap of $87.47 million, a price-to-earnings ratio of -2.63 and a beta of 1.53. The business has a 50 day moving average of $1.41 and a 200-day moving average of $0.75.

Equillium (NASDAQ:EQ - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). As a group, analysts expect that Equillium will post 0.14 earnings per share for the current year.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.